AVIR

Atea Pharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality4/10
  • Growth 1/10
  • Value 4/10
Atea Pharmaceuticals sales and earnings growth
AVIR Growth
Low
  • Revenue Y/Y 0.00%
  • EPS Y/Y 3.00%
  • FCF Y/Y 2.56%
Atea Pharmaceuticals gross and profit margin trends
AVIR Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -41.77%
Atea Pharmaceuticals net debt vs free cash flow
AVIR Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage 999.0

Atea Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗